Novavax (NVAX) to Release Earnings on Wednesday

Novavax (NASDAQ:NVAX - Get Free Report) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Novavax to post earnings of ($0.67) per share and revenue of $90.93 million for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Novavax Price Performance

Shares of NASDAQ:NVAX traded up $0.07 during midday trading on Friday, reaching $7.99. The company had a trading volume of 10,281,850 shares, compared to its average volume of 4,357,510. The stock has a market capitalization of $1.28 billion, a P/E ratio of -3.54, a PEG ratio of 2.88 and a beta of 2.14. The stock's fifty day moving average price is $8.68 and its 200-day moving average price is $10.14. Novavax has a one year low of $3.81 and a one year high of $23.86.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $19.00 target price on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, Novavax has an average rating of "Hold" and a consensus price target of $17.83.

Insiders Place Their Bets

In related news, Director Rachel K. King sold 4,150 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James F. Young sold 4,600 shares of the company's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total value of $39,008.00. Following the transaction, the director now owns 57,160 shares of the company's stock, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock valued at $119,641 over the last 90 days. 1.00% of the stock is owned by company insiders.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.